Projects per year
Personal profile
Research interests
Dr. Gavin Robertson's research program focuses on malignant melanoma, the most deadly form of skin cancer. The central goal of his program is to unravel the biology and signaling pathways involved in melanoma tumor development in order to develop the next generation of therapeutic agents to treat this disease. Specifically, it involves identification and validation of novel therapeutic targets, discovery and development of new therapies and clinical evaluation of these drugs in patients.
Generally,the types of studies occurring the Robertson laboratory are:
Genetic and cell culture studies using animal and human models are used to identify and validate the involvement of candidate melanoma-causing genes. A recent example is the discovery of Akt3 involvement in approximately 70 percent of human melanomas.
Drug screens and medicinal chemistry are used to identify and develop new therapeutic agents. A recent example is the melanoma-treating drug ISC-4, which targets Akt3 signaling.
Nanotechnology and bioengineering are used to better deliver experimental agents into cancer cells. A recent example of this is the use of nanoliposomes and ultrasound that deliver therapeutic siRNA into melanoma cells.
Finally, agents are tested in the clinic for toxicity and tumor inhibitory efficacy. A recent example is a killed mycobacterium called CADI-5 that is being evaluated in clinical trials.
The ultimate goal of Dr. Robertson's translational research program is to develop better therapeutics for the treatment of melanoma based on the biology of the disease.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
Targeting Aldehyde Dehydrogenase for Cancer Prevention
Robertson, G., Amin, S. & Schell, T.
4/15/20 → 3/31/24
Project: Research project
-
-
-
Akt3 Signaling as a Therapeutic Target
Robertson, G. P. & Robertson, G.
12/17/07 → 11/30/13
Project: Research project
-
Targeted Chemoprevention Through Inhibition of Akt3 Signaling
9/1/07 → 8/31/10
Project: Research project
-
Development of a novel Bruton’s tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells
Elbezanti, W. O., Al-Odat, O. S., Chitren, R., Singh, J. K., Srivastava, S. K., Gowda, K., Amin, S., Robertson, G. P., Nemmara, V. V., Jonnalagadda, S. C., Budak-Alpdogan, T. & Pandey, M. K., Sep 9 2022, In: Frontiers in Pharmacology. 13, 894535.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Drug-Tolerant Persister Cells in Cancer Therapy Resistance
Dhanyamraju, P. K., Schell, T. D., Amin, S. & Robertson, G. P., Jul 15 2022, In: Cancer Research. 82, 14, p. 2503-2514 12 p.Research output: Contribution to journal › Review article › peer-review
Open Access16 Scopus citations -
Targeting Protein Translation in Melanoma by Inhibiting EEF-2 Kinase Regulates Cholesterol Metabolism though SREBP2 to Inhibit Tumour Development
Dinavahi, S. S., Chen, Y. C., Gowda, R., Dhanyamraju, P. K., Punnath, K., Desai, D., Berg, A., Kimball, S. R., Amin, S., Yang, J. M. & Robertson, G. P., Apr 1 2022, In: International journal of molecular sciences. 23, 7, 3481.Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations -
Targeting WEE1/AKT Restores p53-Dependent Natural Killer–Cell Activation to Induce Immune Checkpoint Blockade Responses in “Cold” Melanoma
Dinavahi, S. S., Chen, Y. C., Punnath, K., Berg, A., Herlyn, M., Foroutan, M., Huntington, N. D. & Robertson, G. P., Jun 2022, In: Cancer Immunology Research. 10, 6, p. 757-769 13 p.Research output: Contribution to journal › Article › peer-review
10 Scopus citations -
Activating Sphingosine-1-phospahte signaling in endothelial cells increases myosin light chain phosphorylation to decrease endothelial permeability thereby inhibiting cancer metastasis
Chen, Y. C., Dinavahi, S. S., Feng, Q., Gowda, R., Ramisetti, S., Xia, X., LaPenna, K. B., Chirasani, V. R., Cho, S. H., Hafenstein, S. L., Battu, M. B., Berg, A., Sharma, A. K., Kirchhausen, T., Dokholyan, N. V., Amin, S., He, P. & Robertson, G. P., May 28 2021, In: Cancer Letters. 506, p. 107-119 13 p.Research output: Contribution to journal › Article › peer-review
3 Scopus citations